Financhill
Sell
19

CRSP Quote, Financials, Valuation and Earnings

Last price:
$42.12
Seasonality move :
6.36%
Day range:
$41.94 - $43.48
52-week range:
$36.52 - $75.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.87x
Volume:
1.4M
Avg. volume:
2.4M
1-year change:
-41.51%
Market cap:
$3.6B
Revenue:
$35M
EPS (TTM):
-$4.37

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CRSP
CRISPR Therapeutics AG
$7.3M -$1.19 -96.36% -11.56% $83.60
ACIU
AC Immune SA
$820.9K -$0.21 -95.08% -273.39% $10.08
ADXN
Addex Therapeutics
$177.2K -- 2.35% -- $30.00
MOLN
Molecular Partners AG
-- -$0.45 -100% -8.38% $10.78
NLSP
NLS Pharmaceutics
-- -- -- -- --
VRTX
Vertex Pharmaceuticals
$2.8B $4.02 5.83% 2.33% $496.78
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CRSP
CRISPR Therapeutics AG
$42.12 $83.60 $3.6B -- $0.00 0% --
ACIU
AC Immune SA
$2.29 $10.08 $226.6M -- $0.00 0% --
ADXN
Addex Therapeutics
$7.54 $30.00 $8.1M -- $0.00 0% 13.93x
MOLN
Molecular Partners AG
$4.33 $10.78 $159.7M -- $0.00 0% 21.67x
NLSP
NLS Pharmaceutics
$1.58 -- $6M -- $0.00 0% --
VRTX
Vertex Pharmaceuticals
$504.77 $496.78 $129.6B 26.10x $0.00 0% 11.88x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CRSP
CRISPR Therapeutics AG
-- 2.038 -- 21.97x
ACIU
AC Immune SA
-- 5.657 -- 1.66x
ADXN
Addex Therapeutics
-- 3.522 -- 4.36x
MOLN
Molecular Partners AG
-- 3.153 -- 14.08x
NLSP
NLS Pharmaceutics
-- 3.791 -- --
VRTX
Vertex Pharmaceuticals
-- 1.364 -- 2.17x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CRSP
CRISPR Therapeutics AG
$35M -$64.6M -18.65% -18.65% -184.54% -$50.3M
ACIU
AC Immune SA
-- -$21.2M -37.26% -37.26% -1386.46% $5.4M
ADXN
Addex Therapeutics
-- -$719.5K 91.08% 91.08% -2836.3% -$713.3K
MOLN
Molecular Partners AG
-- -$16.8M -37.36% -37.36% -2407.93% -$14.2M
NLSP
NLS Pharmaceutics
-- -- -- -- -- --
VRTX
Vertex Pharmaceuticals
$2.5B $1.1B -3.23% -3.23% 39.12% $492M

CRISPR Therapeutics AG vs. Competitors

  • Which has Higher Returns CRSP or ACIU?

    AC Immune SA has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of -1389.36%. CRISPR Therapeutics AG's return on equity of -18.65% beat AC Immune SA's return on equity of -37.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRSP
    CRISPR Therapeutics AG
    -- -$0.44 $1.9B
    ACIU
    AC Immune SA
    -- -$0.18 $124.3M
  • What do Analysts Say About CRSP or ACIU?

    CRISPR Therapeutics AG has a consensus price target of $83.60, signalling upside risk potential of 98.48%. On the other hand AC Immune SA has an analysts' consensus of $10.08 which suggests that it could grow by 340.11%. Given that AC Immune SA has higher upside potential than CRISPR Therapeutics AG, analysts believe AC Immune SA is more attractive than CRISPR Therapeutics AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRSP
    CRISPR Therapeutics AG
    12 11 1
    ACIU
    AC Immune SA
    3 0 0
  • Is CRSP or ACIU More Risky?

    CRISPR Therapeutics AG has a beta of 1.767, which suggesting that the stock is 76.677% more volatile than S&P 500. In comparison AC Immune SA has a beta of 1.226, suggesting its more volatile than the S&P 500 by 22.632%.

  • Which is a Better Dividend Stock CRSP or ACIU?

    CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRSP or ACIU?

    CRISPR Therapeutics AG quarterly revenues are $35M, which are larger than AC Immune SA quarterly revenues of $1.3M. CRISPR Therapeutics AG's net income of -$37.3M is lower than AC Immune SA's net income of -$18M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus -- for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$37.3M
    ACIU
    AC Immune SA
    -- -- $1.3M -$18M
  • Which has Higher Returns CRSP or ADXN?

    Addex Therapeutics has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of -2841.85%. CRISPR Therapeutics AG's return on equity of -18.65% beat Addex Therapeutics's return on equity of 91.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRSP
    CRISPR Therapeutics AG
    -- -$0.44 $1.9B
    ADXN
    Addex Therapeutics
    -- -$2.78 $13.1M
  • What do Analysts Say About CRSP or ADXN?

    CRISPR Therapeutics AG has a consensus price target of $83.60, signalling upside risk potential of 98.48%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 297.88%. Given that Addex Therapeutics has higher upside potential than CRISPR Therapeutics AG, analysts believe Addex Therapeutics is more attractive than CRISPR Therapeutics AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRSP
    CRISPR Therapeutics AG
    12 11 1
    ADXN
    Addex Therapeutics
    0 0 0
  • Is CRSP or ADXN More Risky?

    CRISPR Therapeutics AG has a beta of 1.767, which suggesting that the stock is 76.677% more volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.757, suggesting its more volatile than the S&P 500 by 75.723%.

  • Which is a Better Dividend Stock CRSP or ADXN?

    CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRSP or ADXN?

    CRISPR Therapeutics AG quarterly revenues are $35M, which are larger than Addex Therapeutics quarterly revenues of $62.3K. CRISPR Therapeutics AG's net income of -$37.3M is lower than Addex Therapeutics's net income of -$1.8M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 13.93x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$37.3M
    ADXN
    Addex Therapeutics
    13.93x -- $62.3K -$1.8M
  • Which has Higher Returns CRSP or MOLN?

    Molecular Partners AG has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of -2408.81%. CRISPR Therapeutics AG's return on equity of -18.65% beat Molecular Partners AG's return on equity of -37.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRSP
    CRISPR Therapeutics AG
    -- -$0.44 $1.9B
    MOLN
    Molecular Partners AG
    -- -$0.34 $165M
  • What do Analysts Say About CRSP or MOLN?

    CRISPR Therapeutics AG has a consensus price target of $83.60, signalling upside risk potential of 98.48%. On the other hand Molecular Partners AG has an analysts' consensus of $10.78 which suggests that it could grow by 148.97%. Given that Molecular Partners AG has higher upside potential than CRISPR Therapeutics AG, analysts believe Molecular Partners AG is more attractive than CRISPR Therapeutics AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRSP
    CRISPR Therapeutics AG
    12 11 1
    MOLN
    Molecular Partners AG
    3 1 0
  • Is CRSP or MOLN More Risky?

    CRISPR Therapeutics AG has a beta of 1.767, which suggesting that the stock is 76.677% more volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CRSP or MOLN?

    CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRSP or MOLN?

    CRISPR Therapeutics AG quarterly revenues are $35M, which are larger than Molecular Partners AG quarterly revenues of $787.5K. CRISPR Therapeutics AG's net income of -$37.3M is lower than Molecular Partners AG's net income of -$12.8M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 21.67x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$37.3M
    MOLN
    Molecular Partners AG
    21.67x -- $787.5K -$12.8M
  • Which has Higher Returns CRSP or NLSP?

    NLS Pharmaceutics has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of --. CRISPR Therapeutics AG's return on equity of -18.65% beat NLS Pharmaceutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CRSP
    CRISPR Therapeutics AG
    -- -$0.44 $1.9B
    NLSP
    NLS Pharmaceutics
    -- -- --
  • What do Analysts Say About CRSP or NLSP?

    CRISPR Therapeutics AG has a consensus price target of $83.60, signalling upside risk potential of 98.48%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 15089.87%. Given that NLS Pharmaceutics has higher upside potential than CRISPR Therapeutics AG, analysts believe NLS Pharmaceutics is more attractive than CRISPR Therapeutics AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRSP
    CRISPR Therapeutics AG
    12 11 1
    NLSP
    NLS Pharmaceutics
    0 0 0
  • Is CRSP or NLSP More Risky?

    CRISPR Therapeutics AG has a beta of 1.767, which suggesting that the stock is 76.677% more volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CRSP or NLSP?

    CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRSP or NLSP?

    CRISPR Therapeutics AG quarterly revenues are $35M, which are larger than NLS Pharmaceutics quarterly revenues of --. CRISPR Therapeutics AG's net income of -$37.3M is higher than NLS Pharmaceutics's net income of --. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$37.3M
    NLSP
    NLS Pharmaceutics
    -- -- -- --
  • Which has Higher Returns CRSP or VRTX?

    Vertex Pharmaceuticals has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of 31.35%. CRISPR Therapeutics AG's return on equity of -18.65% beat Vertex Pharmaceuticals's return on equity of -3.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRSP
    CRISPR Therapeutics AG
    -- -$0.44 $1.9B
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
  • What do Analysts Say About CRSP or VRTX?

    CRISPR Therapeutics AG has a consensus price target of $83.60, signalling upside risk potential of 98.48%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.78 which suggests that it could fall by -1.58%. Given that CRISPR Therapeutics AG has higher upside potential than Vertex Pharmaceuticals, analysts believe CRISPR Therapeutics AG is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRSP
    CRISPR Therapeutics AG
    12 11 1
    VRTX
    Vertex Pharmaceuticals
    16 12 1
  • Is CRSP or VRTX More Risky?

    CRISPR Therapeutics AG has a beta of 1.767, which suggesting that the stock is 76.677% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

  • Which is a Better Dividend Stock CRSP or VRTX?

    CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRSP or VRTX?

    CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. CRISPR Therapeutics AG's net income of -$37.3M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 11.88x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$37.3M
    VRTX
    Vertex Pharmaceuticals
    11.88x 26.10x $2.9B $913M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock